ClinicalTrials.gg
CompletedNCT01623713Updated Nov 19, 2013

Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia

A Phase 2 interventional study of iloperidone and Risperidone in Schizophrenia, Iloperidone and Efficacy, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-11-19.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing iloperidone in Schizophrenia — 2 open to participants now, 2 under way, 1 of them phase 3. iloperidone · Schizophrenia.

Enrollment
6th of 11
260 · median 260
Started
2012
with 1 other
Phase 2
Only one
of the 11
Registered
5th of 11
by date
Lead sponsor
1 of 11
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Among the 11 studies testing iloperidone in Schizophrenia, this one is the 6th largest by enrollment, is one of 2 that started in 2012, is the only one in phase 2, and was the 5th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 11 studies testing iloperidone in Schizophrenia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About iloperidone

iloperidone: first FDA approval 2009 (FANAPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing iloperidone in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether iloperidone is effective in the treatment of Schizophrenia.

03

Conditions studied

  • Schizophrenia
  • Iloperidone
  • Efficacy

Browse trials for

Keywords

  • schizophrenia
  • iloperidone
  • Risperidone
  • Efficacy
  • Safety
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women ages 18-65 years old.
  • diagnosis of schizophrenia.
  • PANSS≥70.
  • Of the 7 PANSS positive symptom subscale, at least two score ≥ 4 points.
  • Written .

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing (lactating) women, or women who plan on conceiving during the course of the study.
  • disease of the heart,kidneys,liver,hematonosis or endocrine system.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
260 participants (actual)

Study arms

  • Active comparator
    Risperidone

    Drug: Risperidone

  • Experimental
    iloperidone

    Drug: iloperidone

Interventions

  • Iloperidone is being development as a treatment of schizophrenia. This trial will verify the safety and efficacy of iloperidone in patients with schizophrenia.

  • Risperidone is used for the treatment of schizophrenia.Risperidone is unique among most other atypicals in that it has high affinity for the D2 receptor whereas most other atypicals have 'loose binding' of the D2 receptor. It has actions at several 5-HT (serotonin) receptor subtypes.

06

What researchers measure

Primary outcomes

  1. Positive and Negative Symptom Scale(PANSS)-Total Score

    Time frame: 6 weeks

Secondary outcomes

  1. Effective percentage(PANSS score reduce rate≥50%)

    Time frame: 6 weeks

  2. Change in scores from baseline to end point assessment on the PANSS Positive subscale (PANSS-P)

    Time frame: 6 weeks

  3. Change in scores from baseline to end point assessment on the PANSS Negative subscale (PANSS-N)

    Time frame: 6 weeks

  4. Change in scores from baseline to end point assessment on the PANSS General Psychopathology subscale(PANSS-GP)

    Time frame: 6 weeks

07

Study locations

1 site
  • Sixth Hospital of Peking University
    Peking, Beijing 100191, China
08

References and documents

Publications

  • Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005 Sep 22;353(12):1209-23. doi: 10.1056/NEJMoa051688. Epub 2005 Sep 19. Erratum In: N Engl J Med. 2010 Sep 9;363(11):1092-3. PubMed 16172203 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2012, a primary completion of Oct 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2012
First posted
Jun 20, 2012
Start
Jun 2012
Primary completionActual
Oct 2013
CompletionActual
Nov 2013
Last update
Nov 19, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01623713
Responsible party
Sponsor
First posted
Jun 20, 2012
Start date
Jun 2012
Primary completion
Oct 2013
Completion
Nov 2013
Last update
Nov 19, 2013

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iloperidone

Start the discussion